Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 12/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245808 | 0.83 | FGFR1 (0.48) | EP300FGFR1 | |
| SCHEMBL27723178 | 0.83 | FGFR1 (0.48) | EP300FGFR1 | |
| SCHEMBL13975422 | 0.83 | FGFR1 (0.48) | EP300FGFR1 | |
| SCHEMBL25628523 | 0.83 | FGFR1 (0.48) | EP300FGFR1 | |
| SCHEMBL27977634 | 0.83 | FGFR1 (0.48) | EP300FGFR1 | |
| SCHEMBL23343373 | 0.82 | FGFR1 (0.44) | EP300FGFR1CYP2D6DNMT1HDAC1 | |
| SCHEMBL13261399 | 0.81 | TLR8 (0.47) | EP300FGFR1 | |
| SCHEMBL6551980 | 0.80 | FGFR1 (0.45) | EP300FGFR1CYP2D6DNMT1HDAC1 | |
| SCHEMBL19631097 | 0.80 | FGFR1 (0.45) | EP300FGFR1SLC22A6 | |
| SCHEMBL8840764 | 0.80 | FGFR1 (0.41) | EP300FGFR1CYP2D6DNMT1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | EP300 3376/4885FGFR1 1245/4885CYP2D6 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.